hronic coronary artery disease (CAD) is most commonly the result of obstruction of the coronary arteries by atheromatous plaques. However, coronary artery spasm, which is defined as an abnormal contraction of an epicardial coronary artery that results in myocardial ischemia, is also often observed and plays an important role in the pathogenesis of ischemic heart disease in Japan. 1 Endothelial-derived nitric oxide (NO) is a key determinant of coronary artery spasm, and is synthesized by endothelial NO synthase (eNOS). 1 Adiponectin has a protective action against the initiation and progression of atherosclerosis through its anti-inflammatory and anti-atherosclerotic effects. 2, 3 In cultured endothelial cells adiponectin also ameliorates the suppression of eNOS activity, leading to increased NO production. 2 Patients with CAD have low levels of adiponectin 2 and clinically, low plasma levels of adiponectin have been also reported to be associated with vascular endothelial dysfunction in humans. 4 However, the relationship between adiponectin and coronary artery spasm, both of which are closely involved in coronary endothelial dysfunction, has not been elucidated and so the hypothesis of the present study was that adiponectin may be associated with coronary spastic angina (CSA).
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Methods
We enrolled 110 Japanese men who underwent diagnostic cardiac catheterization at Kumamoto University Hospital (age: 63.6±9.9 years, mean ± SD, range: 34-82 years). The group with CSA comprised 55 consecutive patients who fulfilled both inclusion criteria: (a) spontaneous anginal attacks associated with ST-segment elevation or depression on the ECG at rest; and (b) coronary artery spasm demonstrated angiographically by intracoronary infusion of acetylcholine (ACh). 5 The chest pain syndrome (CPS) group comprised 55 subjects in whom coronary artery spasm could not be provoked in any coronary artery by intracoronary infusion of ACh. The CPS group was matched for age and body mass index (BMI) with the CSA group. Incremental doses of ACh were infused into the left and right coronary arteries separately as described previously. 5 Coronary artery spasm was defined as brief total or subtotal occlusion of the epicardial coronary arteries associated with chest pain and/or ischemic ST-segment changes on the electrocardiogram. Neither group had ≥25% organic coronary artery stenosis and none of the patients were taking any type of thiazolidinediones or calcium antagonists. Plasma adiponectin levels were determined by an enzymelinked immunosorbent assay as described previously. 6 All data are expressed as mean ± SD. Differences in frequencies were analyzed by the chi-square test. Differences in continuous variables between 2 groups were examined using an unpaired t-test. Because the distribution of the levels of plasma adiponectin, serum triglyceride, and Creactive protein were skewed, logarithmically transformed values were used for statistical analysis. To examine the independent factors for CSA, multiple logistic regression analysis was performed including the variables that were significant in simple logistic regression analysis. A p-value <0.05 was considered statistically significant. Table 1 shows the clinical and biochemical characteristics of both groups. Plasma log-adiponectin levels were significantly lower in the CSA group compared with the CPS group (0.61±0.28 vs 0.80±0.21 g/ml, p<0.0001). The prevalence of cigarette smoking was significantly higher in the CSA group than in the CPS group. High-density lipoprotein cholesterol (HDL-C) levels were significantly lower in the CSA group than in the CPS group.
Multiple logistic regression analysis revealed that hypoadiponectinemia is a predictive risk factor for coronary artery spasm, even after adjustment for cigarette smoking and HDL-C, which were significant in the simple logistic regression ( Table 2 ).
Discussion
The plasma adiponectin level is considered to be a marker of atheromatous vascular changes, 7 and smoking is a significant predictive risk factor for coronary artery spasm, 8 but the relationship between adiponectin and coronary artery spasm has not been determined to date. In this study, we showed that plasma adiponectin levels were significantly lower in the CSA group than in the CPS group and that low levels of plasma adiponectin were closely related to the presence of CSA, independent of cigarette smoking.
Endothelial dysfunction together with reduced endothelial vasodilatory function and smooth muscle hypercontraction in coronary arteries may play an important role in the pathogenesis of coronary artery spasm. 1 In particular, NO, which is recognized as an endothelium-derived relaxing factor, is deficient in patients with CSA. 1 Cigarette smoking is considered to be a major risk factor for CSA 1 because the oxidative stress associated with cigarette smoking may be a source of free radicals, which may cause coronary artery spasm by reducing NO activity. 1 On the other hand, a recent report indicates that adiponectin stimulates the production of NO in vascular endothelial cells 2 and furthermore, that hypoadiponectinemia is associated with impaired endothelium-dependent vasorelaxation, based on significantly re- duced ACh-induced vasorelaxation in adiponectin-knockout mice compared with wild-type mice. 4 In the present study, we demonstrated that adiponectin is a significant determinant of coronary artery spasm, irrespective of cigarette smoking, which suggests that the mechanism(s) by which hypoadiponectinemia impairs endothelium-dependent vasodilatation of the coronary arteries is different from that of cigarette smoking. Although the exact mechanism(s) of adiponectin-induced endothelium-dependent relaxation of coronary arteries is unknown, several potential mechanisms have been speculated. Hypoadiponectinemia is associated with insulin resistance and metabolic syndrome 9 and adiponectin may restore impaired endothelial vasomotor function through improvement of insulin resistance and its associated metabolic abnormalities. Adiponectin may also increase NO production in coronary vascular endothelial cells by activating adenosine monophosphate-activated protein kinase, which in turn promotes eNOS via activation of phosphatidylinositol 3-kinase-Akt-dependent pathways in endothelial cells. 10 The potential limitation of this study is that the subjects were all men, who have significantly lower plasma adiponectin concentrations than BMI-adjusted women. 6, 9 Further studies are warranted to evaluate the significance of plasma adiponectin concentrations in the prevalence of coronary artery spasm in women.
In conclusion, low adiponectin level is associated with CSA in men, independent of cigarette smoking, and hypoadiponectinemia is a potential important risk factor for CSA.
